MedPath

Tagged News

City of Hope to Present Groundbreaking Cancer Research at AACR Annual Meeting 2025

AIOncologyMonoclonal AntibodyPrecision Medicine
  • City of Hope researchers will present over 74 sessions at the AACR Annual Meeting 2025, showcasing innovative work in AI, precision medicine, and immunotherapies for various cancers.
  • A phase 3 clinical trial led by Dr. Aditya Shreenivas demonstrated that penpulimab combined with chemotherapy significantly improved progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
  • Novel AI tools and spatial transcriptomic technologies developed at City of Hope are advancing precision medicine approaches and revealing unique genetic changes in early-onset colorectal cancer among Hispanic and Latino patients.

Pneumonia Antibiotic Piperacillin Shows Promise as Targeted Lyme Disease Treatment at 100-Fold Lower Doses

Precision Medicine
  • Northwestern University researchers screened nearly 500 FDA-approved compounds and identified piperacillin as a potentially more effective Lyme disease treatment than current standard doxycycline therapy.
  • Piperacillin demonstrated effectiveness against Borrelia burgdorferi at doses 100 times lower than doxycycline in pre-clinical mouse studies, while avoiding broad-spectrum antibiotic side effects.
  • A companion study revealed that lingering peptidoglycan from Lyme bacteria persists in joint fluid and liver tissue, potentially contributing to chronic symptoms similar to Long COVID.
  • The findings suggest piperacillin could address treatment failures in up to 20% of patients who don't respond to doxycycline, offering a precision therapy approach for Lyme disease.

Neurovation Labs Secures Patent for Novel PTSD Biomarker Detection Technology

AINeurologyPrecision Medicine
• Neurovation Labs has been granted U.S. Patent No. 12,274,761 for technology that detects GluA1-containing AMPA receptors in the brain, enabling objective PTSD diagnosis.
• The patented radiological imaging device represents a significant advancement in mental health diagnostics by providing a physiological biomarker for a condition traditionally diagnosed through subjective assessments.
• Beyond PTSD, Neurovation Labs is exploring applications of this technology for other neurological conditions including traumatic brain injury, Alzheimer's disease, and epilepsy.

University of Glasgow and myDNA Partner to Advance Pharmacogenomics Integration in NHS Healthcare

Precision MedicineReal World Evidence
  • The University of Glasgow's Living Laboratory for Precision Medicine has partnered with myDNA to generate real-world evidence supporting pharmacogenomics adoption in healthcare systems.
  • The collaboration aims to assess clinical benefits and cost-effectiveness of personalized drug selection based on individual genetic profiles, moving away from traditional "one-size-fits-all" medication approaches.
  • The partnership will focus on integrating pharmacogenomics into everyday clinical practice across Scotland and the NHS, with potential global impact for healthcare systems worldwide.
  • The initiative seeks to improve medication safety and efficacy for patients while contributing to significant cost savings for healthcare systems through precision medicine strategies.

Eli Lilly Commits $1.3 Billion to Verve Therapeutics' Cardiovascular Gene Therapy Platform

Precision MedicineGene Editing
  • Eli Lilly has made a $1.3 billion investment commitment to Verve Therapeutics, marking a significant bet on cardiovascular gene therapy development.
  • The partnership represents one of the largest investments in cardiovascular gene therapy, highlighting the potential of this emerging therapeutic approach.
  • Verve Therapeutics has received FDA Fast Track designation for its cardiovascular gene therapy programs, accelerating the regulatory pathway.
  • The collaboration positions both companies at the forefront of next-generation cardiovascular treatments targeting genetic causes of heart disease.

PGxAI Launches Deneb: AI Model to Revolutionize Drug Development Through Pharmacogenetics

AIPrecision Medicine
  • PGxAI has introduced Deneb, an advanced AI model that integrates molecular structures, physicochemical properties, and genetic profiles to deliver real-time pharmacogenetic recommendations for drug development.
  • The new platform helps biopharmaceutical companies and CROs identify optimal patient cohorts, refine dosing strategies, and predict adverse reactions before clinical trials begin, significantly reducing development costs and failures.
  • By automating traditionally manual PGx guideline creation processes, Deneb enables more targeted, data-driven approaches to drug development, potentially accelerating regulatory approvals and bringing safer therapies to market faster.

Abu Dhabi Launches Multi-Partner Initiative to Advance Precision Medicine and Genomic Healthcare

Precision MedicineAI
  • Abu Dhabi's Department of Health signed a landmark MoU with six major partners including PureHealth, M42, Illumina, and leading universities to establish a collaborative framework for precision medicine and advanced therapies.
  • The partnership will focus on building genomic infrastructure tailored to Emirati populations, launching R&D initiatives in gene therapy and cell-based treatments, and integrating AI platforms for genomic data analysis.
  • This initiative builds on Abu Dhabi's existing Emirati Genome Programme, which has already collected over 430,000 genome samples, positioning the emirate as a global life sciences hub.
  • The collaboration aims to transform healthcare from a one-size-fits-all approach to deeply personalized, preventive care targeting oncology, rare genetic diseases, and metabolic disorders.

Once-Weekly Insulin Icodec Combined with CGM Shows Promising Results for Type 2 Diabetes Management

Precision Medicine
  • Adults with type 2 diabetes achieved significant HbA1c reduction from 8.18% to 7% over 26 weeks using once-weekly insulin icodec combined with continuous glucose monitoring in the ONWARDS 9 trial.
  • Time in range improved dramatically by more than 20 percentage points, equivalent to an additional 5 hours and 11 minutes of optimal glucose control per day.
  • The combination therapy showed excellent safety profile with no severe hypoglycemic events and only 13 clinically significant episodes among 51 participants.
  • Researchers suggest this approach could advance precision diabetes management and potentially complement GLP-1 therapies for patients struggling to achieve target HbA1c levels.

Overcoming Barriers and Obstacles to Adopting Diabetes Devices

NCT04161131CompletedNot Applicable
Molly Tanenbaum
Posted 12/9/2019

Real-World Evidence Oncology Market Projected to Reach $3.51 Billion by 2035 with 14.7% CAGR

Real World EvidenceOncologyAIPrecision Medicine
  • The real-world evidence oncology solutions market is projected to grow from $893 million in 2025 to $3.51 billion by 2035, representing a compound annual growth rate of 14.7%.
  • Market growth is driven by increasing demand for real-world evidence in drug development, rising focus on value-based healthcare, growing global cancer incidence, and advancements in data analytics and AI technologies.
  • North America is expected to hold the largest market share in 2025, while the Asia-Pacific region is projected to experience the fastest growth during the forecast period.
  • The datasets segment is expected to account for the largest market share, while pharmaceutical, biotechnology, and medical device companies represent the primary end-user segment.

AstraZeneca's Camizestrant Shows 56% Reduction in Breast Cancer Progression Risk Using Blood Test-Guided Treatment

Precision Medicine
  • AstraZeneca's experimental drug camizestrant reduced the risk of disease progression or death by 56% in patients with hormone receptor-positive, HER2-negative breast cancer when guided by liquid biopsy testing.
  • The SERENA-6 Phase III trial demonstrated that switching to camizestrant upon detection of ESR1 mutations extended median progression-free survival to 16 months compared to 9.2 months with standard therapy.
  • This represents the first global trial to show that using circulating tumor DNA blood tests to guide treatment changes before clinical progression has significant clinical benefit for breast cancer patients.
  • The study establishes a new treatment paradigm where resistance can be detected and addressed proactively, potentially delaying the need for chemotherapy and keeping patients on first-line therapy longer.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.